[Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)].
On the basis of reports in the literature and of our own clinical experience it appears that melanocyte inhibiting factor (MIF) is a very promising therapeutic agent in the management of Parkinson's disease. Besides theoretical considerations relating to biochemical and pathophysiological spheres, the question of the current dosage for clinical usage seems to be of the utmost importance. We are of the opinion that the currently-employed dosage of 400 mg daily is still too low. Hence, the present investigation will be continued with a view to establishing the optimum dosage for maximal therapeutic effect.
D000368:Aged; D004295:Dihydroxyphenylalanine / Q000378:metabolism; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D009075:MSH Release-Inhibiting Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000628:therapy*
D004295:Dihydroxyphenylalanine; D009075:MSH Release-Inhibiting Hormone
Infusionstherapie mit MIF (Melanocyte Inhibiting Factor) beim Parkinson-Syndrom